Updating the database of the Illinois Compiled Statutes (ILCS) is an ongoing process.
Recent laws may not yet be included in the ILCS database, but they are found on this site as
Public
Acts soon after they become law. For information concerning the relationship between statutes and Public Acts, refer to the
Guide.
Because the statute database is maintained primarily for legislative drafting purposes,
statutory changes are sometimes included in the statute database before they take effect.
If the source note at the end of a Section of the statutes includes a Public Act that has
not yet taken effect, the version of the law that is currently in effect may have already
been removed from the database and you should refer to that Public Act to see the changes
made to the current law.
(410 ILCS 240/3.4) Sec. 3.4. Adrenoleukodystrophy. In accordance with the timetable specified in this Section, the Department shall provide all newborns with screening tests for the presence of adrenoleukodystrophy (ALD). The testing shall begin within 18 months following the occurrence of all of the following: (1) the development and validation of a reliable |
| methodology for screening newborns for ALD using dried blood spots and quality assurance testing methodology for such test or the approval of a test for ALD using dried blood spots by the federal Food and Drug Administration;
|
|
(2) the availability of any necessary reagents for
|
|
(3) the establishment and verification of relevant
|
| and appropriate performance specifications as defined under the federal Clinical Laboratory Improvement Amendments and regulations thereunder for Federal Drug Administration-cleared or in-house developed methods, performed under an institutional review board approved protocol, if required;
|
|
(4) the availability of quality assurance testing and
|
| comparative threshold values for ALD;
|
|
(5) the acquisition and installment by the Department
|
| of the equipment necessary to implement the initial pilot and statewide volume of screening tests for ALD;
|
|
(6) the establishment of precise threshold values
|
| ensuring defined disorder identification for ALD;
|
|
(7) the authentication of pilot testing achieving
|
| each milestone described in items (1) through (6) of this Section for ALD; and
|
|
(8) the authentication of achieving the potential of
|
| high throughput standards for statewide volume of ALD concomitant with each milestone described in items (1) through (6) of this Section.
|
|
The Department is authorized to implement an additional fee for the screening no sooner than 6 months prior to beginning the testing in order to accumulate the resources for start-up and other costs associated with implementation of the screening and thereafter to support the costs associated with screening and follow-up programs for adrenoleukodystrophy.
(Source: P.A. 99-403, eff. 8-19-15.)
|
